ResMed Q2 Adj $1.88 Beats $1.79 Estimate, Sales $1.16B Beat $1.15B Estimate
Portfolio Pulse from Benzinga Newsdesk
ResMed (NYSE:RMD) reported Q2 adjusted earnings of $1.88 per share, surpassing the consensus estimate of $1.79, and marking a 13.25% increase from the previous year. Sales reached $1.16B, slightly above the $1.15B estimate, representing a 12.48% year-over-year growth.
January 24, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ResMed exceeded Q2 earnings and sales estimates, with EPS at $1.88 against a $1.79 forecast and sales of $1.16B versus the expected $1.15B.
Beating both earnings and sales estimates typically leads to positive investor sentiment and can result in a short-term stock price increase. The reported growth from the same period last year further strengthens the case for a potential uptick in ResMed's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100